Cure Alzheimer's Fund Cure Alzheimer's Fund

Anti-APOE Antibodies

2010

In this project, the researchers hypothesize that targeting apoE, a component of amyloid plaques, can result in less Aβ aggregation in the brain and decreased Aβ-related pathology and that this treatment will have fewer side effects than the use of anti-Aβ antibodies. The project will test this hypothesis in this proposal in the context of human apoE isoforms.

David Holtzman Studies of APOE Translational

Funding to Date

$100,000

Focus

Studies of APOE, Translational

Researchers

David M. Holtzman, M.D.

Related Content:


APOE in Choroid Plexus Function and Related Alzheimer’s Disease Pathogenesis Guojun Bu 2024-12-16 Fleming APOE Consortium: APOE4 Accelerates CD8 Exhaustion via Glucocorticoid Signaling in Alzheimer’s Female Carriers Oleg Butovsky Vijay K. Kuchroo 2024-11-20 Fleming APOE Consortium: Cell Autonomous Roles of Protective APOE Variants in Microglia in Response to Amyloid Pathology Michael Haney 2024-11-20 Fleming APOE Consortium: Investigating Potential Cell Autonomous Neuroprotection of APOE Protective Variants David Holtzman 2024-11-20 2024 Jeffrey L. Morby Prize for Exceptional Research David Holtzman 2024-07-03 Non-Invasive Delivery of IL-2 to the CNS for Local Expansion of Regulatory T Cells and Prevention of Neurodegeneration in Tauopathy Peter M. Tessier David Holtzman 2024-06-26 Circuit Dynamics in APOE4 Mice Ksenia Kastanenka 2024-06-17 Neuroproteasomes Mechanistically Connect APOE Isoforms to Endogenous Tau Aggregation Kapil V. Ramachandran 2023-12-21